Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Johnson & Johnson announced that management will hold a fireside chat at 11:15 am, Est, on Monday, January 12, 2026. It will also be presented as a live audio webcast on J&J’s investor relations site.

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. Novartis ...

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...

In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.